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Abstract
Pharmacogenomics  is  the  branch  of  pharmacology  which 
deals with the influence of genetic variation on drug response in 
patients by correlating gene expression or single-nucleotide poly-
morphisms with a drug’s efficacy or toxicity. It aims to develop 
rational means to optimize drug therapy, with respect to the pa-
tient’s genotype, to ensure maximum efficacy with minimal ad-
verse effects. Such approaches promise the advent of ‘personalized 
medicine’, in which drugs and drug combinations are optimized for 
each individual’s unique genetic makeup. Pharmacogenomics is the 
whole genome application of pharmacogenetics, which examines 
the single gene interactions with drugs.
Keywords:  Pharmacogenetics; Single nucleotide polymorphisms; 
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Introduction
  Pharmacogenomics is the study of how an individual’s 
genetic inheritance affects the body’s response to drugs. The 
term comes from the words pharmacology and genomics 
and is thus the intersection of pharmaceuticals and genetics. 
Pharmacogenomics holds the promise that drugs might one 
day be tailor-made for individuals and adapted to each per-
son’s own genetic makeup. Environment, diet, age, lifestyle, 
and state of health all can influence a person’s response to 
medicines, but understanding an individual’s genetic make-
up is thought to be the key to creating personalized drugs 
with greater efficacy and safety. The way a person responds 
to a drug (this includes both positive and negative reactions) 
is a complex trait that is influenced by many different genes. 
Without knowing all of the genes involved in drug response, 
scientists have found it difficult to develop genetic tests that 
could predict a person’s response to a particular drug [1]. 
Once scientists discovered that people’s genes show small 
variations (or changes) in their nucleotide (DNA base) con-
tent, all of that changed: genetic testing for predicting drug 
response is now possible. Pharmacogenomics combines tra-
ditional pharmaceutical sciences such as biochemistry with 
annotated knowledge of genes, proteins, and single nucle-
otide polymorphisms. The most common variations in the 
human genome are called single nucleotide polymorphisms 
(SNPs). There is estimated to be approximately 11 million 
SNPs in the human population, with an average of one every 
1,300 base pairs.
 
History
  Genomics  was  established  by  Fred  Sanger  when  he 
first sequenced the complete genomes of a virus and a mito-
chondrion. His group established techniques of sequencing, 
genome mapping, data storage, and bioinformatic analyses 
in the 1970-1980s. The actual term ‘genomics’ is thought to 
have been coined by Dr. Tom Roderick, a geneticist at the 
Jackson Laboratory (Bar Harbor, ME) over beer at a meeting 
held in Maryland on the mapping of the human genome in 
1986.
  In 1972, Walter Fiers and his team at the Laboratory of 
Molecular Biology of the University of Ghent (Ghent, Bel-
gium) were the first to determine the sequence of a gene: 
the gene for Bacteriophage MS2 coat protein. In 1976, the 
team determined the complete nucleotide-sequence of bac-
teriophage MS2-RNA.  The first DNA-based genome to be 
sequenced in its entirety was that of bacteriophage Φ-X174 
(5,368 bp), sequenced by Frederick Sanger in 1977 [2, 3]. 
  The first free-living organism to be sequenced was that 
of Haemophilus influenzae in 1995, and since then genomes 
are being sequenced at a rapid pace. A rough draft of the hu-
man genome was completed by the Human Genome Project 
in early 2001, creating much fanfare.
 As  of  September  2007,  the  complete  sequence  was 
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known  of  about  1879  viruses,  577  bacterial  species  and 
roughly 23 eukaryote organisms, of which about half are 
fungi. Most of the bacteria whose genomes have been com-
pletely sequenced are problematic disease-causing agents, 
such as Haemophilus influenzae. Pharmacogenomics com-
bines traditional pharmaceutical sciences such as biochemis-
try with annotated knowledge of genes, proteins, and single 
nucleotide polymorphisms [4, 5]. 
 
Importance of pharmacogenomics
   Adverse Drug Reaction conveys little of the horror of a 
severe negative reaction to a prescribed drug. But such nega-
tive reactions can nonetheless occur. A 1998 study of hospital-
ized patients published in the Journal of the American Medi-
cal Association reported that in 1994, adverse drug reactions 
accounted for more than 2.2 million serious cases and over 
100,000 deaths, making adverse drug reactions (ADRs) one 
of the leading causes of hospitalization and death in the Unit-
ed States [6].  For instance, the daily doses required to treat 
patients vary by 20-fold for the warfarin, by 40-fold for the 
antihypertensive drug propranolol and by 60-fold for L-dopa 
for parkinson’s disease. Other drugs have clinical utility in a 
subset of patients with given pathology, e.g., antipsychotics 
that are ineffective in 30% of schizophrenics, suggesting that 
such drugs are only effective in patients with specific disease 
etiologies [7]. Many of the deaths could be avoided if the 
physician had prior knowledge of patient’s genetic profile, 
which determines the drug response. Currently, there is no 
simple way to determine whether people will respond well, 
badly, or not at all to a medication; therefore, pharmaceutical 
companies are limited to developing drugs using a ‘one size 
fits all’ system [8]. This system allows for the development 
of drugs to which the ‘average’ patient will respond. But, as 
the statistics above show, one size does not fit all, sometimes 
with devastating results. What is needed is a way to solve 
the problem of ADRs before they happen. The solution is in 
sight though, and it is called pharmacogenomics. 
  Pharmacogenomics eventually can lead to an overall 
decrease in the cost of health care because of decreases in: 
(1) the number of adverse drug reactions; (2) the number of 
failed drug trials; (3) the time it takes to get a drug approved; 
(4) the length of time patients are on medication; (5) the 
number of medications patients must take to find an effec-
tive therapy; (6) the effects of a disease on the body (through 
early detection) [9]. 
Pharmacogenomics today
  
   The cytochrome P450 (CYP) family of liver enzymes is 
responsible for breaking down more than 30 different classes 
of drugs. DNA variations in genes that code for these en-
zymes can influence their ability to metabolize certain drugs. 
Less active or inactive forms of CYP enzymes that are un-
able to break down and efficiently eliminate drugs from the 
body can cause drug overdose in patients. Today, clinical tri-
als researchers use genetic tests for variations in cytochrome 
P450 genes to screen and monitor patients. In addition, many 
pharmaceutical companies screen their chemical compounds 
to see how well they are broken down by variant forms of 
CYP enzymes [10]. 
  Another enzyme called TPMT (thiopurine methyltrans-
ferase) plays an important role in the chemotherapy treat-
ment of a common childhood leukemia by breaking down 
thiopurines. A small percentage of Caucasians have genetic 
variants that prevent them from producing an active form of 
this protein. As a result, thiopurines elevate to toxic levels in 
the patient because the inactive form of TMPT is unable to 
break down the drug. Today, doctors can use a genetic test to 
screen patients for this deficiency, and the TMPT activity is 
monitored to determine appropriate thiopurine dosage levels 
[11].
Pharmacogenomics in future
       New developments in this field will impact on drug de-
sign at three main levels: (1) the interaction of the drug with 
its receptor binding site; (2) the absorption and distribution 
of the drug; (3) the elimination of the drug from the body.
 
Benefits of pharmacogenomics
   Pharmacogenomics combines traditional pharmaceuti-
cal sciences such as biochemistry with annotated knowledge 
of  genes,  proteins,  and  single  nucleotide  polymorphisms. 
Following are the benefits.
 
More powerful medicines
  Pharmaceutical companies will be able to create drugs 
based on the proteins, enzymes, and RNA molecules associ-
ated with genes and diseases. This will facilitate drug dis-
covery and allow drug makers to produce a therapy more 
targeted  to  specific  diseases. This  accuracy  will  not  only 
maximize therapeutic effects but also decrease damage to 
nearby healthy cells. 
 
Better, safer drugs the first time 
 Instead of the standard trial-and-error method of match-
ing patients with the right drugs, doctors will be able to ana-
lyze a patient’s genetic profile and prescribe the best avail-
able drug therapy from the beginning. Not only will this take 
the guesswork out of finding the right drug, it will speed re-
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covery time and increase safety as the likelihood of adverse 
reactions is eliminated. 
 
More accurate methods of determining appropriate drug 
dosages 
  Current methods of basing dosages on weight and age 
will be replaced with dosages based on a person’s genetics; 
how well the body processes the medicine and the time it 
takes to metabolize it. This will maximize the therapy’s val-
ue and decrease the likelihood of overdose. 
 
Advanced screening for disease 
  Knowing  one’s  genetic  code  will  allow  a  person  to 
make adequate lifestyle and environmental changes at an 
early age so as to avoid or lessen the severity of a genetic 
disease. Likewise, advance knowledge of particular disease 
susceptibility will allow careful monitoring, and treatments 
can be introduced at the most appropriate stage to maximize 
their therapy. 
 
Better vaccines 
 Vaccines made of genetic material, either DNA or RNA, 
promise all the benefits of existing vaccines without all the 
risks. They will activate the immune system but will be un-
able to cause infections. They will be inexpensive, stable, 
easy to store, and capable of being engineered to carry sev-
eral strains of a pathogen at once. 
 
Improvements in the drug discovery and approval pro-
cess
           
  Pharmaceutical companies will be able to discover po-
tential therapies more easily using genome targets. The drug 
approval process should be facilitated as trials are targeted 
for specific genetic population groups and providing greater 
degrees of success. The cost and risk of clinical trials will be 
reduced by targeting only those persons capable of respond-
ing to a drug. 
 
Decrease in the overall cost of health care 
  Decreases in the number of adverse drug reactions, the 
number of failed drug trials, the time it takes to get a drug 
approved, the length of time patients are on medication, the 
number of medications patients must take to find an effec-
tive therapy, the effects of a disease on the body (through 
early detection), and an increase in the range of possible drug 
targets will promote a net decrease in the cost of health care 
[12].
 
Barriers to pharmacogenomics progress
  Pharmacogenomics is a developing research field that 
is still in its infancy. Several of the following barriers will 
have to be overcome before many pharmacogenomics ben-
efits can be realized. They are the followings.
 
Complexity of finding gene variations that affect drug 
response 
        
  Single nucleotide polymorphisms (SNPs) are DNA se-
quence variations that occur when a single nucleotide (A, 
T, C, or G) in the genome sequence is altered. SNPs occur 
every 100 to 300 bases along the 3-billion-base human ge-
nome, therefore millions of SNPs must be identified and 
analyzed to determine their involvement (if any) in drug re-
sponse. Further complicating of the process is our limited 
knowledge of which genes are involved with each drug re-
sponse. Since many genes are likely to influence responses, 
obtaining the big picture on the impact of gene variations is 
highly time-consuming and complicated.
 
Limited drug alternatives 
       
  Only one or two approved drugs may be available for 
treatment  of  a  particular  condition.  If  patients  have  gene 
variations that prevent them using these drugs, they may be 
left without any alternatives for treatment.
 
Disincentives for drug companies to make multiple phar-
macogenomic products
  Most pharmaceutical companies have been successful 
with their ‘one size fits all’ approach to drug development. 
Since it costs hundreds of millions of dollars to bring a drug 
to market, will these companies be willing to develop alter-
native drugs that serve only a small portion of the population 
[13]?
 
Impact on pharmacy profession
  Presently doctors diagnose and prescribe a drug on the 
trial and error basis and pharmacist advices about side ef-
fects and drug-drug interaction .But a day will come when 
you will take a gene report instead of blood reports .Thus 
after the diagnosis, pharmacist would interpret the panels of 
genetic results and advice you which drug would be best for 
your particular gene so that you have fast recovery.
 
Conclusions
  Pharmacogenomics in pharmaceutical industry is a po-
tential tool, awaiting use for the maximum benefit. It repre-
sents a radical advance in medical history. The main aims 
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of it are; personalized therapy, improvement in efficacy and 
reduction in adverse drug reactions, correlation of genotype 
with clinical genotype, identification of novel targets for new 
drugs, and pharmacogenetic profiling of patients to predict 
disease susceptibility and drug response. In the past, most 
drugs were designed to work on the population level rather 
than being targeted for the individual patient. By reversing 
that trend, pharmacogenomics helps to refine the focus of 
treatment and makes drugs more effective and less toxic. 
Rather than relying on the outward manifestation of disease 
– the signs and symptoms that physicians call the phenotype 
– pharmacogenomic medicine examines and treats the geno-
type. Gradual inclusion of pharmacogenomic studies in drug 
discovery and development will cause substantial reduction 
in the expenses involved in drug development, ensure a safe 
clinical trial and reduce failures. Thus, many potential drugs 
which may be lost due to the effects on the outliers in a study 
can be retained when pharmacogenomic study is used in the 
future.
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